A randomised controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalised with COVID-19: the C19-ACS trial

BACKGROUND: Patients hospitalised with COVID-19 suffer thrombotic complications. Risk factors for poor outcomes are shared with coronary artery disease. OBJECTIVES: To investigate efficacy of an acute coronary syndrome regimen in patients hospitalised with COVID-19 and coronary disease risk factors. PATIENTS/METHODS: A randomised controlled open-label trial across acute hospitals (UK and Brazil) added aspirin, clopidogrel, low-dose rivaroxaban, atorvastatin, and omeprazole to standard care for 28-days. Primary efficacy and safety outcomes were 30-day mortality and bleeding. The key secondary outcome was a daily clinical status (at home, in hospital, on intensive therapy unit admission, death). RESULTS: 320 patients from 9 centres were randomised. The trial terminated early due to low recruitment. At 30 days there was no significant difference in mortality (intervention: 11.5% vs control: 15%, unadjusted OR 0.73, 95%CI 0.38 to 1.41, p=0.355). Significant bleeds were infrequent and not significantly different between the arms (intervention: 1.9% vs control 1.9%, p>0.999). Using a Bayesian Markov longitudinal ordinal model, it was 93% probable that intervention arm participants were more likely to transition to a better clinical state each day (OR 1.46, 95% CrI 0.88 to 2.37, Pr(Beta>0)=93%; adjusted OR 1.50, 95% CrI 0.91 to 2.45, Pr(Beta>0)=95%) and median time to discharge home was two days shorter (95% CrI -4 to 0, 2% probability that it was worse). CONCLUSIONS: Acute coronary syndrome treatment regimen was associated with a reduction in the length of hospital stay without an excess in major bleeding. A larger trial is needed to evaluate mortality

Перевод лингвистических средств отображения невербального компонента «улыбка» в англоязычных художественных текстах

The paper is dedicated to the study of language means representing the non-verbal component “smile” in English literary texts as well as to the ways of their translation into Ukrainian. In the article the authors outline typical features of the smile as a universal non-verbal sign of communication, viewed as an indicator of the speaker’s emotional and psychological states. Having analyzed the functional role of a smile in communication, which directly affects the specificity of its nomination in literary texts, the authors systematize the language means of its representation in English. They come to a conclusion that depending on a type of the communicative situation “the smile” can render a range of emotive and evaluative shades of meanings, verbalized in the text by means of combining lexical units of primary and secondary nominations. As a result of the study of text fragments containing nominations of the non-verbal component “smile” the authors generalize the ways of their translation into Ukrainian, identifying the following transformations as the most frequent ones: word-for-word translation, grammatical replacement, modulation. The paper also substantiates the expediency of defining the correlation between emotive potential of different nominations of “smile” in English literary texts and their translations into Ukrainian.Статтю присвячено вивченню мовних засобів відображення невербального компонента комунікації «посмішка» в англомовних художніх текстах, а також установленню способів їх перекладу на українську мову. За результатами аналізу лексикографічного та ілюстративного матеріалів здійснено розгляд специфіки номінації посмішки як універсального невербального знака комунікації з притаманними йому номінативними, емотивними і прагматичними особливостями, систематизовано мовні засоби позначення «посмішки» в англомовному художньому тексті, а також узагальнено способи їх перекладу на українську мову. Обґрунтовано доцільність подальшого дослідження особливостей перекладу невербального компонента комунікації «посмішка» на українську мову з урахуванням емоційно-прагматичного потенціалу його номінацій в англомовних художніх текстах.Статья посвящена изучению языковых средств отображения невербального компонента коммуникации «улыбка» в англоязычных художественных текстах, а также установлению способов их перевода на украинский язык. По результатам анализа лексикографического и иллюстративного материалов осуществлено рассмотрение специфики номинации улыбки как универсального невербального знака коммуникации с присущими ему номинативных, эмотивными и прагматичными особенностями, систематизированы языковые средства, обозначающие «улыбку» в англоязычном художественном тексте, а также обобщены способы их перевода на украинский язык. Обоснована целесообразность дальнейшего исследования особенностей перевода невербального компонента коммуникации «улыбка» на украинский язык с учетом эмоционально-прагматического потенциала его номинаций в англоязычных художественных текстах

Переклад мовних засобів відображення невербального компонента «посмішка» в англомовних художніх текстах

The paper is dedicated to the study of language means representing the non-verbal component “smile” in English literary texts as well as to the ways of their translation into Ukrainian. In the article the authors outline typical features of the smile as a universal non-verbal sign of communication, viewed as an indicator of the speaker’s emotional and psychological states. Having analyzed the functional role of a smile in communication, which directly affects the specificity of its nomination in literary texts, the authors systematize the language means of its representation in English. They come to a conclusion that depending on a type of the communicative situation “the smile” can render a range of emotive and evaluative shades of meanings, verbalized in the text by means of combining lexical units of primary and secondary nominations. As a result of the study of text fragments containing nominations of the non-verbal component “smile” the authors generalize the ways of their translation into Ukrainian, identifying the following transformations as the most frequent ones: word-for-word translation, grammatical replacement, modulation. The paper also substantiates the expediency of defining the correlation between emotive potential of different nominations of “smile” in English literary texts and their translations into Ukrainian.Статья посвящена изучению языковых средств отображения невербального компонента коммуникации «улыбка» в англоязычных художественных текстах, а также установлению способов их перевода на украинский язык. По результатам анализа лексикографического и иллюстративного материалов осуществлено рассмотрение специфики номинации улыбки как универсального невербального знака коммуникации с присущими ему номинативных, эмотивными и прагматичными особенностями, систематизированы языковые средства, обозначающие «улыбку» в англоязычном художественном тексте, а также обобщены способы их перевода на украинский язык. Обоснована целесообразность дальнейшего исследования особенностей перевода невербального компонента коммуникации «улыбка» на украинский язык с учетом эмоционально-прагматического потенциала его номинаций в англоязычных художественных текстах.Статтю присвячено вивченню мовних засобів відображення невербального компонента комунікації «посмішка» в англомовних художніх текстах, а також установленню способів їх перекладу на українську мову. За результатами аналізу лексикографічного та ілюстративного матеріалів здійснено розгляд специфіки номінації посмішки як універсального невербального знака комунікації з притаманними йому номінативними, емотивними і прагматичними особливостями, систематизовано мовні засоби позначення «посмішки» в англомовному художньому тексті, а також узагальнено способи їх перекладу на українську мову. Обґрунтовано доцільність подальшого дослідження особливостей перекладу невербального компонента комунікації «посмішка» на українську мову з урахуванням емоційно-прагматичного потенціалу його номінацій в англомовних художніх текстах

A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial.

BackgroundPatients hospitalized with COVID-19 suffer thrombotic complications. Risk factors for poor outcomes are shared with coronary artery disease.ObjectivesTo investigate the efficacy of an acute coronary syndrome regimen in patients hospitalized with COVID-19 and coronary disease risk factors.MethodsA randomized controlled, open-label trial across acute hospitals (United Kingdom and Brazil) added aspirin, clopidogrel, low-dose rivaroxaban, atorvastatin, and omeprazole to standard care for 28 days. Primary efficacy and safety outcomes were 30-day mortality and bleeding. The key secondary outcome was a daily clinical status (at home, in hospital, on intensive therapy unit admission, or death).ResultsThree hundred twenty patients from 9 centers were randomized. The trial terminated early due to low recruitment. At 30 days, there was no significant difference in mortality (intervention vs control, 11.5% vs 15%; unadjusted odds ratio [OR], 0.73; 95% CI, 0.38-1.41; p = .355). Significant bleeds were infrequent and were not significantly different between the arms (intervention vs control, 1.9% vs 1.9%; p > .999). Using a Bayesian Markov longitudinal ordinal model, it was 93% probable that intervention arm participants were more likely to transition to a better clinical state each day (OR, 1.46; 95% credible interval [CrI], 0.88-2.37; Pr [beta > 0], 93%; adjusted OR, 1.50; 95% CrI, 0.91-2.45; Pr [beta > 0], 95%) and median time to discharge to home was 2 days shorter (95% CrI, -4 to 0; 2% probability that it was worse).ConclusionAcute coronary syndrome treatment regimen was associated with a reduction in the length of hospital stay without an excess in major bleeding. A larger trial is needed to evaluate mortality

A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial.

BACKGROUND: Patients hospitalized with COVID-19 suffer thrombotic complications. Risk factors for poor outcomes are shared with coronary artery disease. OBJECTIVES: To investigate the efficacy of an acute coronary syndrome regimen in patients hospitalized with COVID-19 and coronary disease risk factors. METHODS: A randomized controlled, open-label trial across acute hospitals (United Kingdom and Brazil) added aspirin, clopidogrel, low-dose rivaroxaban, atorvastatin, and omeprazole to standard care for 28 days. Primary efficacy and safety outcomes were 30-day mortality and bleeding. The key secondary outcome was a daily clinical status (at home, in hospital, on intensive therapy unit admission, or death). RESULTS: Three hundred twenty patients from 9 centers were randomized. The trial terminated early due to low recruitment. At 30 days, there was no significant difference in mortality (intervention vs control, 11.5% vs 15%; unadjusted odds ratio [OR], 0.73; 95% CI, 0.38-1.41; p = .355). Significant bleeds were infrequent and were not significantly different between the arms (intervention vs control, 1.9% vs 1.9%; p > .999). Using a Bayesian Markov longitudinal ordinal model, it was 93% probable that intervention arm participants were more likely to transition to a better clinical state each day (OR, 1.46; 95% credible interval [CrI], 0.88-2.37; Pr [beta > 0], 93%; adjusted OR, 1.50; 95% CrI, 0.91-2.45; Pr [beta > 0], 95%) and median time to discharge to home was 2 days shorter (95% CrI, -4 to 0; 2% probability that it was worse). CONCLUSION: Acute coronary syndrome treatment regimen was associated with a reduction in the length of hospital stay without an excess in major bleeding. A larger trial is needed to evaluate mortality